MediMergent Joins CancerX as a Founding Member
MediMergent, a real-world evidence (RWE) company has announced its membership in the CancerX program.
CancerX is a private-public partnership, initiated by the White House as a part of the renewed Cancer Moonshot program. It is a joint initiative by Moffitt Cancer Center, Digital Medicine Society (DiMe), Office for the National Coordinator for Health Information Technology, and the Office of the Assistant Secretary for Health. This collaboration aims to accelerate innovation and breakthroughs in the fight against cancer by bringing together diverse stakeholders to foster greater opportunities and reduce financial burdens associated with cancer care and research.
MediMergent leverages its proprietary technologies in clinical trials, and other patient engagement settings, to demonstrate its impact on health outcomes. Using its suite of serial, interactive, digital surveys, and ML/AI-driven algorithms for advanced analytics, MediMergent supports pharma sponsors, health insurers, and data aggregators in their quest to interrogate big data related to personalized care of cancer patients.
Sandra Garrett, PhD, CEO of MediMergent stated in a press release, "We believe that VOP digital innovations are critical in reshaping the cancer landscape by adding new insights to clinical outcomes and reducing disparities in cancer care delivery among patients. Our relationship with CancerX offers us an unparalleled opportunity to propel digital health practices forward, positively impacting all aspects of the cancer patient's experience."
Ken Borow, MD, chief medical officer of MediMergent discussed the pivotal role of the patient's perspective in the fight against cancer in a press release, "Cancer does not define the patient and treatment must extend well beyond the disease alone. By championing the patient narrative, MediMergent has empowered medical professionals and researchers to gain deeper insights into the unique challenges faced by cancer patients."
"Multi-stakeholder collaboration is critical to harness the potential of digital innovation in the fight against cancer, and we're honored to partner with MediMergent to achieve the ambitious goals of CancerX," said Smit Patel, associate program director at DiMe in a press release. "Through this impressive collaboration, we will establish best practices, build capacity, and demonstrate the impact of innovation on the life of every person on a cancer journey."
Reference
MediMergent Joins CancerX as a Founding Member, Escalating the Voice of the Patient as an Essential Component in the Fight Against Cancer. (2023, August 29). Cision PR Newswire.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
